Инфекционное обострение ХОБЛ: алгоритм лечения


Авдеев С.Н.

ФГУ “НИИ Пульмонологии” ФМБА России, Москва
Обострение ХОБЛ является одной из самых частых причин обращения больных за неотложной медицинской помощью. Среди бактерий наибольшую роль при обострении ХОБЛ играют нетипируемые Haemophilus influenzae, Streptococcus pneumoniae и Moraxella catarrhalis. Современные руководства рекомендуют назначать антибиотики пациентам с наиболее тяжелыми обострениями ХОБЛ, также предложены новые подходы к лечению, основанные на фенотипировании обострений ХОБЛ и определении уровней биомаркеров. При неосложненных обострениях ХОБЛ рекомендовано применение современных макролидов, цефалоспоринов, при осложненных – либо амоксициллин/клавуланат, либо респираторные фторхинолоны (моксифлоксацин, левофлоксацин).

Литература


1. Murray CJL, Lopez AD. Mortality by cause for eight regions of the world: global burden of disease study. Lancet 1997;349:1269–76.
2. Mannino DM, Homa DM, Akinbami LJ, et al. Chronic obstructive pulmonary disease surveillance – United States, 1971–2000. MMWR Surveill Summ 2002;51:1–16.
3. World Health Organization. Global initiative for chronic obstructive lung disease. Geneva (Switzerland): World Health Organization.
4. Zielinski J, MacNee W, Wedzicha J, et al. Causes of death in patients with COPD and chronic respiratory failure. Monaldi Arch Chest Dis 1997;52:43–7.
5. Groenewegen KH, Schols AM, Wouters EF. Mortality and mortality-related factors after hospitalization for acute exacerbation of COPD. Chest 2003;124:459–67.
6. Hurst JR, Vestbo J, Anzueto A, Locantore N, Mьllerova H, Tal-Singer R, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010;363:1128–38.
7. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO workshop report. Last updated 2011. www.goldcopd.org/
8. Donaldson GC, Wedzicha JA. COPD exacerbations: epidemiology. Thorax 2006;61:164–68.
9. Celli BR, Barnes PJ. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Eur Respir J 2007;29: 1224–38.
10. Smeeth L, Thomas SL, Hall AJ, et al. Risk of myocardial infarction and stroke after acute infection or vaccination. N Engl J Med 2004;351:2611–18.
11. Papi A, Bellettato CM, Braccioni F, et al. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am J Respir Crit Care Med 2006;173:1114–21.
12. Veeramachaneni SB, Sethi S. Pathogenesis of bacterial exacerbations of COPD. COPD 2006;3:109–15.
13. Eller J, Ede A, Schaberg T, Niederman MS, Mauch H, Lode H. Infective exacerbations of chronic bronchitis: relation between bacteriologic etiology and lung function. Chest 1998;113:1542–48.
14. Hirschmann JV. Do bacteria cause exacerbations of COPD? Chest 2000;118 :193–203.
15. Puhan MA, Vollenweider D, Latshang T, et al. Exacerbations of chronic obstructive pulmonary
disease: when are antibiotics indicated? A systematic review. Respir Res 2007;8:30.
16. Woodhead M, Blasi F, Ewig S, et al.; European Respiratory Society; European Society of Clinical
Microbiology and Infectious Diseases. Guidelines for the management of adult lower respiratory tract infections. Eur Respir J 2005;26:1138–80.
17. O'Donnell DE, Hernandez P, Kaplan A, et al. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease – 2008 update – highlights for primary care. Can Respir J 2008;15(A):1A–8A.
18. Anthonisen NR, Manfreda J, Warren CP, et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987;106:196–204.
19. Celli BR, MacNee W; ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004;23:932–46.
20. Bafadhel M, McKenna S, Terry S, et al. Acute exacerbations of chronic obstructive pulmonary disease. Identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med 2011;184:662–71.
21. Weis N, Almdal T. C-reactive protein – can it be used as a marker of infection in patients with exacerbation of chronic obstructive pulmonary disease. Eur J Intern Med 2006;17:88–91.
22. Dev D, Sankaran EWR, Cunnife J, et al. Value of C-reactive protein in exacerbation of chronic obstructive pulmonary disease. Respir Med 1998;92:664–67.
23. Авдеев С.Н., Баймаканова Г.Е., Зубаирова П.А. Возможности С-реактивного белка в диагностике бактериальной инфекции и пневмонии у больных с обострением хронической обструктивной болезни легких // Уральский мед. журнал 2008. № 13. C. 19–24.
24. Wilson R, Jones P, Schaberg T, et al. For the Mosaic Study Group. Antibiotic treatment and factors influencing short and long term outcomes of acute exacerbations of chronic bronchitis. Thorax 2006;61:337–42.
25. Sethi S, Murphy TF. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N Engl J Med 2008;359:2355–65.
26. Козлов Р.С., Сивая О.В., Кречикова О.И., Иванчик Н.В. и Группа исследователей проекта “ПеГАС – Динамика резистентности Streptococcus pneumoniae к антибиотикам в России за 1999–2009 гг.” (Результаты многоцентрового проспективного исследования ПеГАС) // Клин. микробиология антимикроб химиотерапия 2010. № 12(4). C. 329–41.
27. Siempos II, Dimopoulos G, Korbila IP, et al. Macrolides, quinolones and amoxicillin/clavulanate for chronic bronchitis: a metaanalysis. Eur Respir J 2007;29:1127–37.
28. O’Donnell JA, Gelone SP. The newer fluoroquinolones. Infect Dis Clin N Am 2004;18:691–716.
29. Blasi F, Tarsia P, Aliberti S, et al. Highlights on the appropriate use of fluoroquinolones in respiratory tract infections. Pulm Pharmacol Therap 2006;19:11–9.
30. Bonfiglio G. Is levofloxacin as active as ciprofloxacin against Pseudomonas aeruginosa? Chemotherapy 2001;47:239–42. 31. Geddes AM, Klugman KP, Rolinson GN. Introduction: historical perspective and
development of amoxicillin/clavulanate. Int J Antimicrob Agents 2007;(2):109–12.
32. McIvor RA. Antibiotics in acute exacerbations of chronic obstructive pulmonary disease. Can Fam
Physician 2009;55:15–6,19–21.
33. Сидоренко С.В., Козлов С.Н. Группа пенициллинов. Практическое руководство по антиинфекционной химиотерапии / Под ред. Л.С. Страчунского, Ю.Б. Белоусова, С.Н. Козлова. М., 2002. C. 47–55.
34. Canut A, Martın-Herrero JE, Labora A, Maortua H. What are the most appropriate antibiotics for the treatment of acute exacerbation of chronic obstructive pulmonary disease? A therapeutic outcomes model. J Antimicrob Chemother 2007;60:605–12.
35. Llor C, Naberan K, Cots JM, et al, on behalf of the EFEMAP. Risk factors for increased cost of exacerbations of chronic bronchitis and chronic obstructive pulmonary disease. Arch Bronconeumol 2006;42:175–82.
36. Wilson R, Anzueto A, Miravitlles M, et al. Moxifloxacin vs amoxicillin/clavulanic acid in outpatient AECOPD: MAESTRAL results. Eur Respir J erj00903-2011; published ahead of print December 1, 2011, doi:10.1183/09031936.00090311.
37. El Moussaoui R, Roede BM, Speelman P, et al. Short-course antibiotic treatment in acute exacerbations of chronic bronchitis and COPD: a meta-analysis of double-blind studies. Thorax 2008;63:415–22.
38. Falagas ME, Avgeri SG, Matthaiou DK, et al. Short-versus long-duration antimicrobial treatment for exacerbations of chronic bronchitis: a meta-analysis. J Antimicrob Chemother 2008;62:442–50.
39. Kardas R. Patient compliance with antibiotic treatment for respiratory tract infections. J Antimicrob Chemother 2002;49:897–903.
40. Christ-Crain M, Jaccard-Stolz D, Bingisser R, et al. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet 2004;363:600–07.


Об авторах / Для корреспонденции


Авдеев Сергей Николаевич – доктор медицинских наук, профессор, руководитель клинического отдела ФГУ “НИИ пульмонологии” ФМБА России. е-mail: serg_avdeev@list.ru


Похожие статьи


Бионика Медиа